Page 1

Revenio Group Corporation : Half - year financial report 1 January - 30 June 2021 The figures in parentheses refer to the corresponding period in the previous year unless otherwise stated . Q2 / 2021 : An excellent quarter , supported by very strong growth in imaging devices April - June 2021 • Net sales totaled EUR 18.9 ( 13.7 ) million , showing an increase of 37.9 % • The currency - adjusted growth of net sales in April - June was 43.0 % , or 5.1 % stronger than the reported growth • • The strong development of business was attributable to good sales performance in all of Revenio's key markets . Sales of imaging devices developed very strongly in the second quarter Operating profit was EUR 4.4 ( 3.4 ) million , or 23.5 % of net sales , up by 28.7 % EBITDA was EUR 5.2 ( 4.1 ) million , up 25.4 % The Oculo acquisition was finalized in April . Oculo is an Australian eye care software platform that combines clinical communication , telehealth , remote patient monitoring , and data analytics capabilities . Oculo's operational development costs will affect the company's relative profitability in 2021 and 2022 Cash flow from operations totaled EUR 4.0 ( 2.9 ) million Undiluted earnings per share came to EUR 0.130 ( 0.097 ) • After the review period , Revenio updated its financial guidance for 2021 January - June 2021 • • • • Net sales totaled EUR 35.6 ( 25.6 ) million , showing an increase of 39.2 % The currency - adjusted growth of net sales in January - June was 43.7 % , or 4.5 % stronger than the reported growth The key products in most markets delivered very strong sales growth Operating profit was EUR 9.0 ( 5.9 ) million , or 25.4 % of net sales , up by 54.1 % . Operating profit adjusted by non - recurring acquisition costs of EUR 0.678 million was EUR 9.7 million , or 27.3 % of net sales , up by 65.7 % EBITDA was EUR 10.4 ( 7.2 ) million , up 45.3 % . EBITDA adjusted by non - recurring acquisition costs of EUR 0.678 million was EUR 11.1 million , or 31.2 % of net sales , up by 54.8 % Cash flow from operations totaled EUR 4.7 ( 2.6 ) million Undiluted earnings per share came to EUR 0.271 ( 0.172 ) On March 17 , 2021 , the Annual General Meeting decided to distribute a dividend of EUR 0.32 ( 0.30 ) per share At its Capital Markets Day held in March , Revenio presented its revised strategy that focuses on clinical eye care solutions